1. Introduction {#sec1-antibiotics-09-00521}
===============

Healthcare-associated infections are those developed by patients as result of care received in hospital (known as nosocomial infections) or any other healthcare setting \[[@B1-antibiotics-09-00521]\]. Nosocomial infections are those that appear at least 72 h after hospital admission and were not previously present or incubating \[[@B2-antibiotics-09-00521],[@B3-antibiotics-09-00521]\]. They indicate the care quality delivered by hospitals and are related to increased morbidity and mortality and a longer hospital stay, representing an important public health problem and increasing healthcare costs \[[@B4-antibiotics-09-00521]\]. Nosocomial infections are estimated to affect 5--10% of patients admitted to hospital \[[@B5-antibiotics-09-00521]\], although their prevalence varies among departments and hospitals, being three- to five-fold higher in intensive care units (ICUs) than in other hospital areas \[[@B6-antibiotics-09-00521],[@B7-antibiotics-09-00521]\]. They are considered to be the sixth cause of death in Europe and the USA, but around one-third of them could be prevented by infection control programs and adequate hygiene measures \[[@B8-antibiotics-09-00521]\]. The magnitude of the attributable mortality is controversial and depends on the type of infection, the severity of the patient (APACHE II scale), and the length of hospital stay, among many other factors \[[@B9-antibiotics-09-00521],[@B10-antibiotics-09-00521]\]. However, the earliest possible prescription of an appropriate empirical antibiotic treatment of nosocomial infections is known to be a key factor to improve the survival of ICU patients \[[@B11-antibiotics-09-00521]\].

In ICU patients, nosocomial infections are often produced by multi-resistant microorganisms \[[@B12-antibiotics-09-00521]\], complicating prescribing decisions. The scant development of new active ingredients has prompted novel strategies to extend the usefulness of existing antibiotics against severe infections \[[@B13-antibiotics-09-00521]\], including the local study of bacterial resistance phenotypes. This allows a more precise selection of antibiotics based on local knowledge of the microorganisms most frequently responsible for infection in each hospital area \[[@B14-antibiotics-09-00521]\].

Since 2012, Spanish hospitals have implemented programs to optimize the use of antibiotics (*Programas de Optimización del Uso de Antimicrobianos* (PROA)). The main objectives are to improve the clinical outcomes of patients with infections; minimize antimicrobial-related adverse effects, including the development and spread of resistance; and promote more effective treatments with lower health costs. PROA recommendations include accessibility to microbiological data, knowledge of bacterial resistance percentages (especially in the hospital area), and the implementation of measures to assist prescribing decisions. Computerized clinical decision support systems have proven useful to meet these objectives \[[@B13-antibiotics-09-00521]\].

PROA implementation in our hospital (Torrecardenas Hospital Complex, Almeria, Spain) led to the development in 2014 of a computerized clinical decision support program for the prescription of antimicrobials, named in Spanish the *Guía Electrónica de Resistencias Hospitalarias* (GERH^®^). Using this system, updated identification and susceptibility data from microbiological studies in all hospitalized patients can be rapidly communicated to physicians using a secure hospital intranet system. Two GERH^®^-based applications were launched: local resistance maps (LRMs) and preliminary microbiological reports with therapeutic recommendations (PMRTRs). To date, these applications have only been available to ICU physicians.

The objective of this study was to evaluate the capacity of LRMs to predict antibiotic susceptibility and resistance profiles and improve the appropriateness of empirical treatments for ICU patients with nosocomial infections, including bacteremia and/or lower respiratory or urinary tract infections.

2. Methods {#sec2-antibiotics-09-00521}
==========

GERH^®^ is based on the Microsoft.NET Framework with Visual C\# and SQL and Open Database Connectivity (ODBC) to the laboratory information system (*Sistema de Información de Laboratorio* (SIL)) of the hospital microbiology laboratory. It is installed on a central server and has been used by ICU physicians since 2014 to consult all susceptibility results stored in the SIL since 2006. The data are organized according to the hospital department, date/date interval, sample type, microorganism/s isolated, and antimicrobials tested, and graphs are created for the ready visualization and interpretation of these data \[[@B15-antibiotics-09-00521]\].

2.1. Local Resistance Maps (LRMs) {#sec2dot1-antibiotics-09-00521}
---------------------------------

LRMs ([Figure 1](#antibiotics-09-00521-f001){ref-type="fig"}) graphically depict information on the frequency of isolated microorganisms ([Figure 1](#antibiotics-09-00521-f001){ref-type="fig"}A), bacterial susceptibility ([Figure 1](#antibiotics-09-00521-f001){ref-type="fig"}B--D), and antibiotic activity ([Figure 1](#antibiotics-09-00521-f001){ref-type="fig"}E). The physicians select and access the graphs via touch screens connected to the hospital intranet. Data are automatically updated every 24 h to include new records from the central GERH^®^ server \[[@B15-antibiotics-09-00521]\].

The LRMs were derived from analyses of the outcomes obtained in all in vitro susceptibility assays for bacteria isolated in ICU patients with bacteremia, lower respiratory tract infection, or urinary tract infection within a defined time interval, commonly the 12-month period before the consultation. The graphs depict accumulated information for the selected time period on the antibiotic susceptibility profile of isolated bacteria, indicating the likelihood that the infection in question is caused by specific bacteria as well as the expected activity of antibiotics against them. This allows the ICU physician to make informed decisions about the treatment of cases based on the local bacterial epidemiology and on the predicted susceptibility profile of the bacteria isolated.

This instrument followed the recommendation of the Spanish Society of Infectious Diseases and Clinical Microbiology (Spanish abbreviation: SEIMC) for accumulated reports on antimicrobial susceptibility to include solely microorganisms obtained from human clinical samples with susceptibility results verified by clinical microbiologists. When the same microorganisms are isolated multiple times in the same patient, those with a change in their resistance phenotype to one or more antibiotics are considered \[[@B16-antibiotics-09-00521]\].

2.2. Study Design {#sec2dot2-antibiotics-09-00521}
-----------------

This retrospective study compared the concordance obtained each year from 2007 to 2016 between susceptibility data from the antibiograms of microorganisms isolated in blood cultures, respiratory samples (bronchial aspirate, bronchial brushing, sputum, bronchoalveolar lavage, and/or tracheal secretion), and/or urine samples from all ICU patients meeting clinical criteria for infection and the susceptibility data depicted by LRMs for the same bacterial species, based on accumulated data for the whole year. In the LRMs, bacteria were defined as susceptible to an antibiotic when at least 75% of clinical isolates of this bacterial species were susceptible according to in vitro tests \[[@B15-antibiotics-09-00521]\]. Concordance was defined as agreement between the susceptibility evaluated by LRMs and the susceptibility obtained in the in vitro study in the microbiology laboratory, i.e. when bacteria were considered as susceptible or resistant by both methods, including "intermediate resistance" within the "resistant" category. There was no concordance when the bacteria were considered susceptible by one approach and resistant by the other. Duplicate bacteria with the same identification and antibiogram were excluded, whether obtained from the same sample or isolated in multiple samples from the same patient.

The adequacy of empirical antibiotic treatments was also retrospectively studied, considering them appropriate when active against the bacterial pathogen causing the infection \[[@B13-antibiotics-09-00521]\]. Accordingly, we determined whether each antibiotic prescribed was active against the bacteria isolated in the different clinical samples from each patient, based on the antibiogram data. The percentage adequacy of empirical prescriptions if they had been based on LRM recommendations was calculated as the number of times that LRM results for the susceptibility of a bacterium to each antibiotic agreed with the result of the susceptibility study as a percentage of the total number of isolates tested. The adequacy of the actual empirical treatment prescribed by physicians was evaluated with reference to the activity of the antibiotic(s) against each bacterium isolated in the different clinical samples according to the corresponding antibiograms. Data on the antibiotics prescribed in ICU patients were retrospectively obtained from the Spanish national nosocomial infection surveillance program (Spanish abbreviation: ENVIN).

Although the instrument is available in the ICU, therapeutic decisions do not have to be based on the data it provides. For this reason, we did not consider or gather data on the compliance of prescribed treatments with LRM recommendations.

2.3. Bacteria Selection {#sec2dot3-antibiotics-09-00521}
-----------------------

Study inclusion criteria for bacteria were: (i) isolation in blood, respiratory, or urine samples; (ii) definitive microbiological species identification; and (iii) belonging to one of the following bacterial groups: (a) *Enterobacteriaceae* (*Citrobacter* spp., *Enterobacter* spp., *Escherichia* spp., *Klebsiella* spp., *Morganella* spp., *Proteus* spp., *Providencia* spp., or *Serratia* spp.); (b) non-fermenting Gram-negative bacilli (*Acinetobacter* spp., *Pseudomonas* spp., and *Stenotrophomonas* spp.)*;* (c) coagulase-positive staphylococci (*Staphylococcus aureus*), and coagulase-negative staphylococci (*Staphylococcus auricularis, Staphylococcus capitis, Staphylococcus epidermidis, Staphylococcus haemolyticus, Staphylococcus hominis, Staphylococcus intermedius, Staphylococcus saprophyticus, Staphylococcus simulans*, and *Staphylococcus warneri*); (d) *Streptococcus pneumoniae*; (e) enterococci (*Enterococcus faecalis* and *Enterococcus faecium*); or (f) *Haemophilus* spp.

2.4. Antibiotic Selection {#sec2dot4-antibiotics-09-00521}
-------------------------

The following antibiotics were included in relation to the above bacteria: (a) amikacin, amoxicillin-clavulanic acid, aztreonam, cefepime, cefotaxime, ceftazidime, ceftriaxone, cefuroxime, ciprofloxacin/levofloxacin, gentamicin, imipenem, meropenem, piperacillin-tazobactam, and tobramycin in *Enterobacteriaceae*; (b) amikacin, cefepime, ceftazidime, ciprofloxacin/levofloxacin, colistin, gentamicin, imipenem, meropenem, piperacillin-tazobactam, and tobramycin in non-fermenting Gram-negative bacilli; (c) ciprofloxacin/levofloxacin, clindamycin, daptomycin, erythromycin, gentamicin, linezolid, oxacillin, rifampicin, teicoplanin, tobramycin, and vancomycin in staphylococci; (d) cefotaxime, levofloxacin, linezolid, and penicillin in *S. pneumoniae*; (e) ampicillin, levofloxacin, daptomycin, linezolid, teicoplanin, and vancomycin in enterococci; and (f) amoxicillin-clavulanic acid, ampicillin, cefotaxime, ciprofloxacin/levofloxacin, and erythromycin in *Haemophilus* spp.

2.5. Study Variables {#sec2dot5-antibiotics-09-00521}
--------------------

Data gathered from antibiogram results, LRMs, and the ENVIN platform were: type of infection, date of sample gathering, type of sample (blood, respiratory, or urine), bacteria identified in each sample, antibiogram of the microorganism(s) isolated, concordance between antibiogram and LRM data, empirical antibiotic treatment prescribed, and concordance with the antibiogram result.

2.6. Statistical analysis {#sec2dot6-antibiotics-09-00521}
-------------------------

In the statistical analysis, the chi-square test was used to compare the adequacy of the actual empirical treatment with the adequacy of the LRM-recommended treatment, considering *p* \< 0.05 to be significant.

3. Results {#sec3-antibiotics-09-00521}
==========

3.1. Concordance Between LRMs and Susceptibility In Vitro {#sec3dot1-antibiotics-09-00521}
---------------------------------------------------------

[Table 1](#antibiotics-09-00521-t001){ref-type="table"} compares the susceptibility data for each bacterium and antibiotic according to in vitro studies with those provided by LRMs after analyzing the information accumulated during the previous year. During the study period (2007--2016), the results of 22,520 in vitro trials were compared to the LRM data, obtaining an average concordance of 73.9%. In other words, the susceptibility or resistance described by LRMs for each bacterium--antibiotic association agreed with the in vitro study results in 73.9% of cases.

For enterobacteria, the concordance ranged from a mean of 95.9% for amikacin over the study period (range 89.7--100%) to mean of 63.6% (range 47.6--86.7%) for ciprofloxacin/levofloxacin. In other words, when an enterobacterium was isolated, the expected susceptibility outcome was the same according to both the LRM and antibiogram in 95.9% of cases for amikacin and in 63.6% of cases for ciprofloxacin/levofloxacin. An intermediate degree of concordance was obtained for the other antibiotics studied.

For non-fermenting Gram-negative bacilli, the concordance widely varied among different antibiotics, obtaining the highest percentage agreement for colistin (88.3%; range 87.5--97.3%) and tobramycin (86.2%; range 58.2--100%) and lower degrees of concordance for amikacin (76.3%; range 42.9--100%), cefepime (54.9%; range 31.3--86.4%), ceftazidime (53.1%; range 28.2--68.8%), ciprofloxacin/levofloxacin (68.8%; range 43.2--88.3%), gentamicin (62.1%; range 34.3--85.0%), piperacillin-tazobactam (60.6%; range 20.0--96.6%), imipenem (49.4%; range 32.4--62.3%), and meropenem (50,7%; range 36.0--71.4%).

For staphylococci, the highest concordance was obtained for daptomycin (99.7%; range 99.0--100%), followed by vancomycin (98.7%; range 95.2--100%), linezolid (92.9%; range 79.4--100%), teicoplanin (92.2%; range 82.1--100%), and rifampicin (90.9%; range 53.6--99.0%). A lower percentage agreement was found for ciprofloxacin/levofloxacin (64.6%; range 54.8--88.6%), clindamycin (60.2%; range 39.6--79.7%), erythromycin (71.0%; range 63,9--84.1%), gentamicin (68.1%; range 53.4--83.1%), oxacillin (71.9%; range 59.5--91.7%), and tobramycin (59.1%; range 50.5--69.7%).

For the remaining bacteria under study (*S. pneumoniae*, enterococci and *Haemophilus* spp.), there were few comparative data and the mean percentage agreement was generally high but showed a very wide range.

Considering all bacteria and antibiotics included in the 22,520 comparisons conducted during the study period, the highest percentage concordance between LRMs and antibiograms was observed for daptomycin (99.7%; range 99.0--100%), vancomycin (98.7%; range 95.5--100%), teicoplanin (92.5%; range 83.0--100%), linezolid (92.3%; range 79.3--100%), and rifampicin (90.9%; range 53.6--99.0%). In summary, the susceptibility data offered by LRMs for bacteria on which the GERH^®^ has this information agrees with the antibiogram result in \>90% of cases.

[Table 2](#antibiotics-09-00521-t002){ref-type="table"} compares the in vitro and LRM susceptibility data for each bacterium and antibiotic by year and by infection type. The mean percentage concordance was 73.5% in lower respiratory tract infections (range 66.5--80.0%), 69.3% in urinary tract infections (range 54.7--81.6%), and 76.1% in bacteremia (range 68.9--80.8%). These findings indicate that the susceptibility information provided by LRMs for these infections is in agreement with the actual susceptibility of the isolated bacteria in 73.5%, 69.3%, and 76.1% of cases, respectively.

3.2. Adequacy of Actual Empirical Prescription and Susceptibility Obtained in the Antibiogram {#sec3dot2-antibiotics-09-00521}
---------------------------------------------------------------------------------------------

[Table 3](#antibiotics-09-00521-t003){ref-type="table"} displays the percentage adequacy of LRM-recommended empirical prescriptions for bacteria in relation to the actual susceptibility observed for them. Antibiotics with a percentage adequacy \>80% in the empirical antibiotic prescription were amikacin, colistin, daptomycin, linezolid, teicoplanin, and vancomycin. Thus, in relation to amikacin, out of 981 isolates of enterobacteria or non-fermenting Gram-negative bacilli isolated in samples, 904 were susceptible to this antibiotic and 77 were resistant, while its use was recommended by LRMs in 854 of cases, giving a percentage adequacy of 87.1%. Accordingly, if amikacin had been used as empirical treatment when recommended by LRMs, this treatment would have been appropriate in 87.1% of cases in which enterobacteria or non-fermenting Gram-negative bacilli were isolated. For daptomycin, linezolid, teicoplanin, and vancomycin the LRM-recommended treatment would have been appropriate in 99.7%, 92.0%, 92.2%, and 98.7% of cases in which a Gram-positive coccus (staphylococcus, enterococcus, or pneumococcus) was isolated.

[Table 4](#antibiotics-09-00521-t004){ref-type="table"} exhibits the percentage adequacy of empirical antibiotic prescriptions if they had followed LRM recommendations, being 57.6% for lower tract respiratory infections, 41.4% for bacteremia, and 54.9% for urinary tract infections. [Table 5](#antibiotics-09-00521-t005){ref-type="table"} lists the percentage adequacy of the empirical antibiotics actually prescribed, being 55.4% for lower respiratory tract infections, 38.3% for bacteremia, and 49.6% for urinary tract infections. Hence, if LRM recommendations had always been followed in the ICU, the percentage adequacy of prescriptions would have been improved by 2.2% for lower respiratory tract infections (57.6% vs. 55.4%; *p* = 0.018), 3.1% for bacteremia (41.4% vs. 38.3%; *p* = 0.070), and 5.3% for urinary tract infections (54.9% vs. 49.6%; *p* = 0.142).

4. Discussion {#sec4-antibiotics-09-00521}
=============

A major factor in the emergence of bacterial resistances is the inappropriate prescription of antibiotics \[[@B17-antibiotics-09-00521]\], estimated to represent 30--50% of all antibiotic prescriptions \[[@B18-antibiotics-09-00521]\]. For this reason, analysis of the antibiotic susceptibility of microorganisms is not only of major epidemiological and clinical importance but provides invaluable support for prescribing decisions. The use of computerized systems based on laboratory susceptibility results assists physicians in the selection of treatments without replacing their own clinical judgement. Various studies have demonstrated that these systems can improve healthcare, reduce inappropriate prescriptions and pharmaceutical costs, monitor antibiotic resistances, and diminish the morbidity and mortality of patients \[[@B15-antibiotics-09-00521],[@B19-antibiotics-09-00521],[@B20-antibiotics-09-00521],[@B21-antibiotics-09-00521]\].

GERH^®^ is integrated within the routine clinical workflow of our ICU, offering a predictive model that provides timely recommendations \[[@B13-antibiotics-09-00521]\] and is designed to increase the percentage of patients who receive appropriate empirical antibiotic therapy, as recommended in previous studies \[[@B22-antibiotics-09-00521],[@B23-antibiotics-09-00521]\]. According to the present findings, LRM-recommended prescriptions would have been appropriate in terms of the susceptibility of isolated bacteria in 57.6% of lower respiratory tract infection cases, 41.4% of bacteremia cases, and 54.9% of urinary tract infection cases. Higher percentages were published for these infections in the ENVIN study (2018), ranging between 63% and 72% \[[@B24-antibiotics-09-00521]\]. Nevertheless, the use of LRMs in our ICU would have significantly improved the adequacy of empirical treatment prescriptions in lower respiratory tract infections by 2.2% (*p* = 0.018), although no significant improvement would have been achieved in the cases of bacteremia (3.1%; *p* = 0.070) or urinary tract infection (5.3%; *p* = 0.142). These improvements are modest but similar to previous reports \[[@B25-antibiotics-09-00521],[@B26-antibiotics-09-00521],[@B27-antibiotics-09-00521]\], contributing to evidence that these systems can assist clinical decision-making and improve the adequacy of empirical antibiotic treatments, as previously affirmed \[[@B28-antibiotics-09-00521]\].

Therapeutic recommendations are provided by LRMs before the responsible microorganism has been defined, and their percentage adequacy is less than when recommendations are made after identifying the etiological agent but before testing its susceptibility \[[@B29-antibiotics-09-00521]\]. This is the case with PMRTRs, another GERH^®^ instrument, whose prescription recommendations were reported to be appropriate in \>82% of cases and to achieve an improvement of 40% in the adequacy of prescriptions for each clinical situation, as we noted in a previous publication \[[@B15-antibiotics-09-00521]\].

The main study limitation was that it did not consider whether or not physicians had consulted LRMs (available since 2014) before prescribing antibiotics, preventing assessment of the impact of LRM consultations over time on the adequacy of empirical antibiotic therapies. LRMs were designed to inform clinicians about the local epidemiology related to nosocomial infections, allowing them to base empirical antibiotic prescriptions on the likelihood of infection with a specific microorganism and on the accumulated activity of different antibiotics against bacteria isolated in a given focus. The aim was not to replace the judgment of clinicians, which may or may not coincide with LRM recommendations. For this reason, clinicians were not asked to state whether or not their prescription followed these recommendations, thereby preserving their prescribing autonomy. As a novel instrument, an adaptation period can be expected before it is accepted and implemented by physicians, who are also influenced by the perception of resulting improvements in antibiotic prescribing and outcomes.

As currently designed, LRMs do not yield information in relation to other PROA objectives such as the improvement in clinical outcomes and the reduction in antibiotic resistance rates, adverse effects, pharmacological interactions, antibiotic consumption, or pharmaceutical costs. These instruments could be improved by the incorporation of new functionalities that monitor and respond to these objectives and tailor empirical therapy recommendations to the clinical situation of each patient. For instance, prescription decisions could be further supported by integrating data for each patient on clinical observations, laboratory results (biochemistry and microbiology), radiology findings, and/or the concentrations of antibiotics in each tissue sample \[[@B30-antibiotics-09-00521]\], along with the antibiotic susceptibility data.

5. Conclusions {#sec5-antibiotics-09-00521}
==============

Although GERH^®^-derived LRMs proved to have a high capacity to predict antibiotic susceptibility and resistance profiles, they produce only a moderate improvement in the adequacy of empirical antibiotic therapy, which is significantly greater in cases of lower respiratory tract infections. According to these findings, LRMs are useful to recommend appropriate prescriptions in approximately 50% of cases but less so in patients with bacteremia or urinary tract infections.
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![GERH^®^-derived local resistance maps (LRMs). The search criteria in LRMs offer different types of graph. As an example, this figure depicts the following: (**A**) graph showing the frequency of isolation of each bacterial species in ICU patients with lower respiratory tract infection between 1 January and 31 December 2015 alongside the accumulated susceptibility; (**B**) graph showing the accumulated susceptibility of *E. coli* in isolates obtained in respiratory samples (bronchial aspirate, bronchial brushing, sputum, bronchoalveolar lavage or tracheal secretion) of ICU patients between 1 January and 31 December 2015; (**C**) graph showing the accumulated susceptibility of *E. coli* in isolates obtained in blood samples of ICU patients between 1 January and 31 December 2015; (**D**) graph showing the accumulated susceptibility of *E. coli* in isolates obtained from urine samples of ICU patients between 1 January and 31 December 2015; and (**E**) graph showing the activity of various antimicrobials, considering the group of microorganisms isolated in respiratory samples of ICU patients between 1 January and 31 December 2015, in which green indicates the percentage of microorganisms of the total tested in which each antibiotic was active. In (**A**--**D**), the percentage of susceptible bacteria is represented using a color code: green for the percentage of susceptible isolates and red for the percentage of isolates with intermediate or resistant clinical category.](antibiotics-09-00521-g001){#antibiotics-09-00521-f001}
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###### 

Percentage concordance between bacterial susceptibility shown by LRMs and susceptibility obtained from antibiograms by year, bacterial group, and antibiotic.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Group/Antibiotic                                     2007     2008   2009     2010   2011     2012   2013     2014   2015     2016   Mean Concordance\                                                                          
                                                                                                                                       2007--2016                                                                                 
  ---------------------------------------------------- -------- ------ -------- ------ -------- ------ -------- ------ -------- ------ ------------------- ------ -------- ------ -------- ------ -------- ------ -------- ------ --------
  ***Enterobacteriaceae***                                                                                                                                                                                                        

  Amikacin                                             100.0%   55     100.0%   61     90.0%    80     93.5%    62     89.7%    39     100.0%              23     100.0%   24     97.0%    101    95.6%    91     97.6%    82     95.9%

  Amoxicillin-clavulanic acid                          69.6%    46     69.0%    42     55.7%    70     61.4%    57     64.9%    37     62.7%               75     66.3%    86     76.2%    122    65.9%    123    59.6%    102    65.5%

  Aztreonam                                            78.9%    19     93.3%    30     76.9%    13     100.0%   1      0.0%     1      \-                  \-     50.0%    2      69.0%    119    62.8%    94     54.3%    81     66.7%

  Cefepime                                             80.4%    51     85.2%    61     81.3%    80     66.1%    62     71.8%    39     71.1%               76     62.9%    89     76.0%    121    68.0%    125    63.1%    103    71.7%

  Cefotaxime                                           72.5%    51     83.6%    55     77.0%    74     65.5%    58     73.0%    37     65.3%               75     61.2%    85     76.1%    109    67.5%    117    59.6%    99     69.3%

  Ceftazidime                                          72.7%    55     88.5%    61     80.2%    81     66.1%    62     71.1%    38     69.7%               76     61.8%    89     74.6%    122    66.9%    127    57.1%    105    70.0%

  Ceftriaxone                                          100.0%   1      \-       \-     \-       \-     \-       \-     100.0%   1      \-                  \-     \-       \-     100.0%   1      \-       \-     \-       \-     100.0%

  Cefuroxime                                           0.0%     3      73.7%    38     63.2%    68     44.1%    34     70.6%    34     60.8%               74     62.3%    86     81.1%    106    73.3%    116    63.8%    94     67.3%

  Ciprofloxacin/Levofloxacin                           80.0%    55     86.7%    60     65.4%    81     69.4%    62     52.5%    40     52.6%               76     70.3%    74     69.1%    123    55.6%    126    47.6%    105    63.6%

  Gentamicin                                           92.6%    54     93.4%    61     78.8%    80     85.2%    61     72.5%    40     57.9%               76     69.7%    89     69.1%    123    61.1%    126    54.8%    104    70.8%

  Imipenem                                             97.9%    48     100.0%   60     96.3%    81     93.5%    62     97.4%    39     94.7%               76     89.9%    89     81.5%    97     92.1%    127    92.3%    104    92.6%

  Meropenem                                            100.0%   33     100.0%   25     100.0%   13     100.0%   2      100.0%   1      \-                  \-     \-       \-     \-       \-     80.0%    5      100.0%   5      98.8%

  Piperacillin-tazobactam                              79.6%    54     88.5%    61     86.7%    30     100.0%   2      100.0%   1      \-                  \-     80.0%    20     62.3%    114    64.8%    125    56.9%    102    69.2%

  Tobramycin                                           96.4%    55     96.7%    61     81.5%    81     83.9%    62     76.9%    39     60.2%               76     65.6%    64     71.1%    121    57.9%    126    52.9%    104    71.2%

  Total general                                        84.7%    580    89.5%    676    78.1%    832    74.6%    587    74.1%    386    67.3%               703    69.5%    797    75.1%    1379   68.8%    1428   63.0%    1190   73.2%

  **Non-fermenting Gram-negative bacilli**                                                                                                                                                                                        

  Amikacin                                             66.7%    60     85.3%    34     90.0%    40     100.0%   32     97.0%    33     100.0%              10     72.7%    11     42.9%    35     81.5%    54     57.4%    54     76.3%

  Cefepime                                             86.4%    59     70.3%    37     50.0%    40     31.3%    32     53.1%    32     58.2%               29     57.1%    35     31.4%    35     61.1%    54     34.6%    55     54.9%

  Ceftazidime                                          62.3%    61     43.2%    37     50.0%    40     34.4%    32     57.6%    33     62.1%               29     62.1%    37     28.2%    39     68.8%    64     49.3%    67     53.1%

  Ciprofloxacin/Levofloxacin                           88.3%    60     68.4%    38     76.2%    42     43.2%    37     55.9%    34     86.7%               30     56.8%    37     55.3%    38     76.6%    64     66.7%    66     68.8%

  Colistin                                             93.9%    33     88.0%    25     94.9%    39     96.6%    29     87.5%    32     100.0%              28     97.3%    37     34.5%    29     86.0%    50     95.7%    47     88.3%

  Gentamicin                                           85.0%    60     62.2%    37     67.5%    40     81.3%    32     75.8%    33     86.2%               29     62.2%    37     34.3%    35     38.9%    54     41.8%    55     62.1%

  Imipenem                                             62.3%    61     32.4%    37     47.5%    40     37.5%    32     48.5%    33     58.6%               29     54.1%    37     53.3%    30     52.9%    51     41.2%    51     49.4%

  Meropenem                                            41.1%    56     71.4%    35     52.5%    40     31.0%    29     46.7%    30     85.7%               28     62.2%    37     36.7%    30     54.0%    50     36.0%    50     50.7%

  Piperacillin-tazobactam                              96.6%    59     90.3%    31     50.0%    40     42.9%    28     31.3%    32     71.4%               28     64.9%    37     20.0%    30     68.6%    51     44.0%    50     60.6%

  Tobramycin                                           95.1%    61     100.0%   37     87.5%    40     96.9%    32     93.9%    33     100.0%              29     81.1%    37     77.1%    35     85.2%    54     58.2%    55     86.2%

  Total general                                        77.9%    610    70.1%    348    66.6%    401    59.4%    315    64.9%    325    79.6%               269    66.7%    342    41.7%    336    67.6%    546    52.4%    550    64.9%

  **Positive coagulase staphylococci (*S. aureus*)**                                                                                                                                                                              

  Ciprofloxacin/Levofloxacin                           57.1%    63     25.0%    28     40.0%    20     27.8%    36     37.5%    24     51.9%               27     66.7%    33     93.5%    31     75.8%    33     70.7%    41     56.2%

  Clindamycin                                          50.8%    63     15.4%    26     57.9%    19     72.2%    36     54.2%    24     51.6%               31     93.9%    33     74.2%    31     90.9%    33     75.6%    41     64.4%

  Daptomycin                                           \-       \-     \-       \-     \-       \-     \-       \-     \-       \-     100.0%              4      69.8%    31     100.0%   29     100.0%   32     100.0%   41     93.2%

  Erythromycin                                         60.9%    64     17.9%    28     52.6%    19     58.3%    36     41.7%    24     35.5%               31     66.7%    33     54.8%    31     63.5%    33     73.2%    41     54.7%

  Gentamicin                                           93.8%    64     96.6%    29     100.0%   9      100.0%   36     100.0%   24     96.8%               31     84.8%    33     90.3%    31     90.9%    33     95.1%    41     94.3%

  Linezolid                                            100.0%   50     100.0%   29     100.0%   14     100.0%   37     100.0%   23     100.0%              31     97.0%    33     100.0%   31     100.0%   32     92.7%    41     98.8%

  Oxacillin                                            59.0%    61     20.7%    29     60.0%    20     18.9%    37     37.5%    24     48.4%               31     66.7%    33     90.3%    31     69.7%    33     65.9%    41     54.4%

  Rifampicin                                           100.0%   45     100.0%   23     100.0%   19     97.3%    37     54.2%    24     100.0%              31     96.4%    28     \-       \-     0.0%     1      \-       \-     93.3%

  Teicoplanin                                          100.0%   64     100.0%   28     100.0%   20     100.0%   37     95.8%    24     100.0%              31     97.0%    33     100.0%   31     100.0%   32     100.0%   40     99.4%

  Tobramycin                                           57.1%    56     24.1%    29     35.0%    20     72.2%    36     54.2%    24     77.4%               31     89.3%    28     \-       \-     \-       \-     \-       \-     59.8%

  Vancomycin                                           100.0%   63     96.6%    29     100.0%   20     100.0%   37     100.0%   23     100.0%              31     97.0%    33     96.8%    31     100.0%   33     100.0%   41     99.1%

  Total general                                        77.1%    593    59.4%    278    73.7%    190    74.8%    365    66.9%    239    76.8%               310    86.3%    351    88.8%    277    87.5%    295    85.9%    368    78.3%

  **Negative coagulase staphylococci**                                                                                                                                                                                            

  Ciprofloxacin/Levofloxacin                           64.3%    42     70.8%    65     67.9%    84     69.4%    72     78.3%    60     56.1%               66     63.5%    74     84.6%    39     82.9%    35     70.8%    24     64.6%

  Clindamycin                                          44.2%    43     49.2%    65     64.3%    84     62.3%    69     65.0%    60     43.5%               69     58.1%    74     65.9%    41     69.4%    36     58.3%    24     60.2%

  Daptomycin                                           \-       \-     \-       \-     \-       \-     \-       \-     \-       \-     100.0%              33     100.0%   72     100.0%   40     100.0%   36     100.0%   21     99.7%

  Erythromycin                                         79.1%    43     84.4%    64     76.2%    84     72.2%    72     79.7%    59     84.1%               69     91.9%    74     70.7%    41     80.5%    36     91.7%    24     71.0%

  Gentamicin                                           58.1%    43     52.3%    65     42.9%    84     52.8%    72     56.7%    60     40.6%               69     48.0%    73     63.4%    41     69.4%    36     62.5%    24     68.1%

  Linezolid                                            100.0%   35     91.5%    59     93.8%    65     100.0%   65     98.2%    56     89.4%               66     87.5%    64     76.3%    38     69.4%    36     54.6%    22     92.9%

  Oxacillin                                            71.4%    42     84.6%    65     75.0%    84     79.7%    74     80.0%    60     79.7%               69     79.5%    73     92.7%    41     88.9%    36     95.8%    24     71.9%

  Rifampicin                                           87.5%    24     90.2%    51     96.4%    84     94.6%    74     53.3%    60     98.6%               69     100.0%   71     87.5%    8      \-       \-     100.0%   2      90.9%

  Teicoplanin                                          86.0%    43     100.0%   65     86.9%    84     91.9%    74     76.7%    60     76.8%               69     81.1%    74     97.6%    41     97.2%    36     100.0%   22     92.2%

  Tobramycin                                           47.6%    42     62.5%    64     56.0%    84     67.1%    73     65.0%    60     49.3%               69     62.0%    71     42.9%    7      \-       \-     \-       \-     59.1%

  Vancomycin                                           100.0%   43     100.0%   65     98.8%    84     100.0%   72     95.0%    60     100.0%              69     94.6%    74     100.0%   41     100.0%   36     100.0%   24     98.7%

  Total general                                        72.7%    400    78.2%    628    75.4%    821    78.9%    717    74.6%    595    73.1%               717    78.6%    794    82.8%    378    84.2%    323    81.5%    211    77.6%

  ***Staphylococcus* spp.**                                                                                                                                                                                                       

  Ciprofloxacin/Levofloxacin                           60.0%    105    57.0%    93     62.5%    104    55.6%    108    66.7%    84     54.8%               93     64.5%    107    88.6%    70     79.4%    68     70.8%    65     64.6%

  Clindamycin                                          48.1%    106    39.6%    91     63.1%    103    65.7%    105    61.9%    84     46.0%               100    69.2%    107    69.4%    72     79.7%    69     69.2%    65     60.2%

  Daptomycin                                           \-       \-     \-       \-     \-       \-     \-       \-     \-       \-     100.0%              37     99.0%    103    100.0%   69     100.0%   68     100.0%   62     99.7%

  Erythromycin                                         68.2%    107    64.1%    92     71.8%    103    67.6%    108    68.7%    83     69.0%               100    84.1%    107    63.9%    72     72.5%    69     80.0%    65     71.0%

  Gentamicin                                           79.4%    107    66.0%    94     53.4%    103    68.5%    108    69.0%    84     58.0%               100    59.4%    106    75.0%    72     79.7%    69     83.1%    65     68.1%

  Linezolid                                            100.0%   85     94.3%    88     94.9%    79     100.0%   102    98.7%    79     92.8%               97     90.7%    97     87.0%    69     83.8%    68     79.4%    63     92.9%

  Oxacillin                                            64.1%    103    64.9%    94     72.1%    104    59.5%    111    67.9%    84     70.0%               100    83.3%    96     91.7%    72     79.7%    69     76.9%    65     71.9%

  Rifampicin                                           95.7%    69     93.2%    74     97.1%    103    95.5%    111    53.6%    84     99.0%               100    99.0%    99     87.5%    8      0.0%     1      100.0%   2      90.9%

  Teicoplanin                                          94.4%    107    100.0%   93     89.4%    104    94.6%    111    82.1%    84     84.0%               100    86.0%    107    98.6%    72     98.5%    68     100.0%   62     92.2%

  Tobramycin                                           53.1%    98     50.5%    93     51.9%    104    68.8%    109    61.9%    84     58.0%               100    69.7%    99     42.9%    7      \-       \-     \-       \-     59.1%

  Vancomycin                                           100.0%   106    98.9%    94     99.0%    104    100.0%   109    95.2%    84     100.0%              100    95.3%    107    98.6%    72     100.0%   69     100.0%   65     98.7%

  Total general                                        75.3%    993    72.4%    906    75.1%    1011   77.5%    1082   72.4%    834    74.2%               1027   81.0%    1148   85.3%    655    85.8%    618    84.3%    579    77.6%

  ***Streptococcus pneumoniae***                                                                                                                                                                                                  

  Cefotaxime                                           85.7%    7      100.0%   7      100.0%   12     100.0%   6      100.0%   3      100.0%              3      100.0%   8      100.0%   4      100.0%   4      100.0%   7      98.4%

  Levofloxacin                                         87.5%    8      80.0%    5      100.0%   12     100.0%   6      100.0%   3      50.0%               2      90.0%    10     100.0%   4      100.0%   4      100.0%   7      93.4%

  Linezolid                                            \-       \-     \-       \-     \-       \-     100.0%   1      100.0%   2      \-                  \-     100.0%   5      \-       \-     100.0%   1      100.0%   7      100.0%

  Penicillin                                           42.9%    7      28.6%    7      41.7%    12     60.0%    5      33.3%    3      100.0%              3      50.0%    10     0.0%     4      100.0%   1      100.0%   6      50.0%

  Total general                                        72.7%    22     68.4%    19     80.6%    36     88.9%    18     81.8%    11     87.5%               8      81.8%    33     66.7%    12     100.0%   10     100.0%   27     82.7%

  **Enterococci**                                                                                                                                                                                                                 

  Ampicillin                                           90.0%    10     88.9%    9      71.4%    7      100.0%   5      100.0%   5      100.0%              4      100.0%   11     100.0%   12     93.3%    15     100.0%   11     94.4%

  Levofloxacin                                         30.8%    13     77.8%    9      85.7%    7      0.0%     5      80.0%    5      100.0%              4      63.6%    11     33.3%    12     57.1%    14     36.4%    11     52.7%

  Daptomycin                                           \-       \-     \-       \-     \-       \-     \-       \-     \-       \-     \-                  \-     \-       \-     100.0%   6      100.0%   13     100.0%   8      100.0%

  Linezolid                                            100.0%   12     100.0%   9      100.0%   7      100.0%   5      80.0%    5      100.0%              4      90.0%    10     100.0%   9      53.9%    13     100.0%   8      90.3%

  Teicoplanin                                          100.0%   12     66.7%    9      100.0%   7      100.0%   5      100.0%   4      100.0%              4      100.0%   10     100.0%   9      100.0%   13     100.0%   8      96.3%

  Vancomycin                                           100.0%   11     100.0%   9      100.0%   7      100.0%   5      100.0%   5      100.0%              4      100.0%   11     100.0%   12     93.3%    15     100.0%   11     98.9%

  Total general                                        82.8%    58     86.7%    45     91.4%    35     80.0%    25     91.7%    24     100.0%              20     90.6%    53     78.3%    60     83.1%    83     87.7%    57     85.9%

  ***Haemophilus* spp.**                                                                                                                                                                                                          

  Amoxicillin-clavulanic acid                          90.0%    10     92.3%    13     80.0%    5      90.0%    10     100.0%   4      100.0%              13     100.0%   12     100.0%   8      100.0%   8      100.0%   8      95.6%

  Ampicillin                                           30.0%    10     30.8%    13     60.0%    5      80.0%    10     75.0%    4      53.8%               13     58.3%    12     12.5%    8      50.0%    8      25.0%    8      46.1%

  Cefotaxime                                           100.0%   10     100.0%   13     100.0%   5      100.0%   10     100.0%   4      100.0%              13     100.0%   12     100.0%   8      100.0%   8      100.0%   8      100.0%

  Ciprofloxacin/Levofloxacin                           100.0%   10     100.0%   13     100.0%   5      100.0%   10     100.0%   4      100.0%              13     100.0%   12     100.0%   8      100.0%   8      100.0%   8      100.0%

  Erythromycin                                         90.0%    10     76.9%    13     80.0%    5      50.0%    10     100.0%   4      15.3%               13     90.9%    11     75.0%    8      62.5%    8      87.5%    8      68.9%

  Total general                                        82.0%    50     80.0%    65     84.0%    25     84.0%    50     95.0%    20     73.8%               65     89.8%    59     77.5%    40     82.5%    40     82.5%    40     82.1%

  **All bacteria**                                                                                                                                                                                                                

  Amikacin                                             82.6%    115    94.7%    95     90.0%    120    95.7%    94     93.1%    72     100.0%              33     91.4%    35     83.1%    136    90.3%    145    81.6%    136    88.7%

  Amoxicillin-clavulanic acid                          73.2%    56     74.5%    55     57.3%    75     65.7%    67     68.3%    41     68.2%               88     70.4%    98     77.7%    130    67.9%    131    62.7%    110    68.7%

  Ampicillin                                           60.0%    20     54.5%    22     66.7%    12     86.7%    15     88.9%    9      64.7%               17     78.3%    23     65.0%    20     78.3%    23     68.4%    19     70.0%

  Aztreonam                                            78.9%    19     93.3%    30     76.9%    13     100.0%   1      0.0%     1      \-                  \-     100.0%   1      69.1%    97     62.8%    94     54.3%    81     66.8%

  Cefepime                                             83.6%    110    79.6%    98     70.8%    120    54.3%    94     63.4%    71     67.6%               105    61.3%    124    66.0%    156    65.9%    179    53.2%    158    66.1%

  Cefotaxime                                           77.9%    68     88.0%    75     81.3%    91     73.0%    74     77.3%    44     71.4%               91     68.6%    105    78.5%    121    70.5%    129    64.9%    114    74.3%

  Ceftazidime                                          67.2%    116    71.4%    98     70.2%    121    55.3%    94     64.8%    71     67.6%               105    61.9%    126    63.4%    161    67.5%    191    54.1%    172    64.1%

  Ceftriaxone                                          100.0%   1      \-       \-     \-       \-     \-       \-     100.0%   1      \-                  \-     \-       \-     100.0%   1      \-       \-     \-       \-     100.0%

  Cefuroxime                                           0.0%     3      73.7%    38     63.2%    68     44.1%    34     70.6%    34     60.8%               74     66.3%    86     81.1%    106    73.3%    116    63.8%    94     67.8%

  Ciprofloxacin/levofloxacin                           72.1%    251    71.1%    218    68.9%    251    59.2%    228    62.9%    170    61.9%               218    67.7%    251    72.2%    255    68.0%    284    60.7%    262    66.7%

  Clindamycin                                          48.1%    106    39.6%    91     63.1%    103    65.7%    105    61.9%    84     46.0%               100    69.2%    107    69.4%    72     79.7%    69     69.2%    65     60.2%

  Colistin                                             93.9%    33     88.0%    25     94.9%    39     96.6%    29     87.5%    32     100.0%              28     97.3%    37     34.5%    29     86.0%    50     95.7%    47     88.3%

  Daptomycin                                           \-       \-     \-       \-     \-       \-     \-       \-     \-       \-     100.0%              37     99.0%    103    100.0%   75     100.0%   81     100.0%   70     99.7%

  Erythromycin                                         70.1%    117    65.7%    105    72.2%    108    66.1%    118    70.1%    87     62.8%               113    84.7%    118    65.0%    80     71.4%    77     80.8%    73     70.8%

  Gentamicin                                           84.2%    221    74.0%    192    65.0%    223    75.6%    201    71.3%    157    61.9%               205    63.8%    232    65.7%    230    61.5%    249    59.8%    224    68.0%

  Imipenem                                             78.0%    109    74.2%    97     80.2%    121    74.5%    94     75.0%    72     84.8%               105    79.4%    126    75.8%    149    80.9%    178    75.5%    155    78.0%

  Linezolid                                            100.0%   97     94.8%    97     95.3%    86     100.0%   108    97.7%    86     93.1%               101    91.1%    112    82.1%    78     79.3%    82     83.9%    78     92.3%

  Meropenem                                            62.9%    89     83.3%    60     64.2%    53     35.5%    31     48.4%    31     85.7%               28     62.2%    37     36.7%    30     56.4%    55     41.8%    55     59.3%

  Oxacillin                                            64.1%    103    64.9%    94     72.1%    104    59.5%    111    67.9%    84     70.0%               100    75.5%    106    91.7%    72     79.7%    69     76.9%    65     71.2%

  Penicillin                                           42.9%    7      28.6%    7      41.7%    12     60.0%    5      33.3%    3      100.0%              3      50.0%    10     0.0%     4      100.0%   1      100.0%   6      50.0%

  Piperacillin-tazobactam                              88.5%    113    89.1%    92     65.7%    70     46.7%    30     33.3%    33     71.4%               28     70.2%    57     53.5%    144    65.9%    176    52.6%    152    65.5%

  Rifampicin                                           95.7%    69     93.2%    74     97.1%    103    95.5%    111    53.6%    84     99.0%               100    99.0%    99     87.5%    8      0.0%     1      100.0%   2      90.9%

  Teicoplanin                                          95.0%    119    97.1%    102    90.1%    111    94.8%    116    83.0%    88     84.6%               104    87.2%    117    98.8%    81     98.8%    81     100.0%   70     92.5%

  Tobramycin                                           76.2%    214    74.9%    191    68.9%    225    77.8%    203    72.4%    156    64.9%               205    70.5%    200    71.2%    163    66.1%    180    54.7%    159    70.0%

  Vancomycin                                           100.0%   117    99.0%    103    99.1%    111    100.0%   114    95.5%    89     100.0%              104    95.8%    118    98.8%    84     98.8%    84     100.0%   76     98.7%

  Total general                                        78.5%    2273   78.1%    2059   75.1%    2340   74.2%    2077   71.9%    1600   72.8%               2092   75.6%    2429   73.3%    2482   73.2%    2725   67.0%    2443   73.9%
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

***C***, the percentage of concordance in the assessment of antibiotic susceptibility of each bacterium between the information provided by LRMs and that obtained in the in vitro susceptibility study; ***N****,* for each year, the number of times in which each antibiotic was tested against bacteria of this group (number of trials with bacterial susceptibility against this antibiotic and comparison with the information provided by LRMs).

antibiotics-09-00521-t002_Table 2

###### 

Percentage of concordance between bacterial susceptibility depicted by LRMs and that obtained from antibiograms by year and type of infection.

  ----------------------- ---------- ---------- ---------- ---------- ----------------------- ---------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- -----
  **Type of infection**   **2007**   **2008**   **2009**   **2010**   **2011**                **2012**                                                                                           

  **C**                   **N**      **M**      **C**      **N**      **M**                   **C**      **N**   **M**   **C**   **N**   **M**   **C**   **N**   **M**   **C**   **N**   **M**   

  **Respiratory**         80.0%      1568       173        79.4%      1081                    117        75.5%   1185    130     72.1%   1076    123     70.8%   768     83      74.4%   1030    118

  **Bacteremia**          74.4%      598        70         75.8%      810                     87         75.7%   904     95      77.6%   843     90      75.6%   697     71      74.7%   883     88

  **Urinary**             79.4%      107        13         81.5%      168                     17         71.3%   251     25      70.9%   158     17      59.3%   135     13      54.7%   179     20

  **All**                 78.5%      2273       256        78.1%      2059                    221        75.1%   2340    250     74.2%   2077    230     71.9%   1600    167     72.8%   2092    226

  **Type of infection**   **2013**   **2014**   **2015**   **2016**   **Mean concordance**\                                                                                                      
                                                                      **2007--2016**                                                                                                             

  **C**                   **N**      **M**      **C**      **N**      **M**                   **C**      **N**   **M**   **C**   **N**   **M**   **C**   **N**   **M**                           

  **Respiratory**         74.4%      1217       142        70.6%      1652                    186        72.4%   1543    159     66.5%   1618    174     73.5%   12738   1405                    

  **Bacteremia**          80.8%      943        92         77.9%      672                     82         76.2%   728     76      68.9%   491     52      76.1%   7569    803                     

  **Urinary**             63.2%      269        32         81.6%      158                     20         70.9%   454     49      66.2%   334     37      69.3%   2213    243                     

  **All**                 75.6%      2429       266        73.3%      2482                    288        73.2%   2725    284     67.0%   2443    263     74.0%   22520   2451                    
  ----------------------- ---------- ---------- ---------- ---------- ----------------------- ---------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- -----

***C***, the percentage agreement on the antibiotic susceptibility of each bacteria between LRMs and in vitro susceptibility studies; ***N***, for each year, the total number of susceptibility studies of bacteria isolated in this type of sample versus the group of antibiotics (number of tests with results for bacterial susceptibility to the antibiotic and comparison with information provided by LRMs); ***M***, for each year, the total number of bacteria isolated in patients with infections of each type.

antibiotics-09-00521-t003_Table 3

###### 

Percentage adequacy of the empirical prescription of an antibiotic if based on LRM recommendations with reference to the actual susceptibility of isolated bacteria.

  Antibiotics                  Clinical Category According to in Vitro Susceptibility Test   Clinical Category Defined by LRMs   Total   Percentage Adequacy   
  ---------------------------- ------------------------------------------------------------- ----------------------------------- ------- --------------------- -------
  Amikacin                     S                                                             854                                 50      904                   87.1%
  R                            61                                                            16                                  77                            
  Amoxicillin-clavulanic       S                                                             251                                 199     450                   29.5%
  R                            67                                                            334                                 401                           
  Ampicillin                   S                                                             108                                 37      145                   60.0%
  R                            17                                                            18                                  35                            
  Aztreonam                    S                                                             133                                 82      215                   39.3%
  R                            31                                                            92                                  123                           
  Cefepime                     S                                                             604                                 281     885                   49.7%
  R                            131                                                           199                                 330                           
  Cefotaxime                   S                                                             538                                 167     705                   59.0%
  R                            67                                                            140                                 207                           
  Ceftazidime                  S                                                             574                                 311     885                   45.7%
  R                            140                                                           230                                 370                           
  Cefuroxime                   S                                                             209                                 156     365                   32.0%
  R                            54                                                            234                                 288                           
  Ciprofloxacin/levofloxacin   S                                                             889                                 612     1501                  37.2%
  R                            184                                                           703                                 887                           
  Clindamycin                  S                                                             195                                 309     504                   21.6%
  R                            50                                                            348                                 398                           
  Colistin                     S                                                             306                                 18      324                   87.7%
  R                            23                                                            2                                   25                            
  Daptomycin                   S                                                             365                                 1       366                   99.7%
  R                            0                                                             0                                   0                             
  Erythromycin                 S                                                             116                                 243     359                   11.6%
  R                            48                                                            589                                 637                           
  Gentamicin                   S                                                             976                                 540     1516                  45.7%
  R                            144                                                           474                                 618                           
  Imipenem                     S                                                             801                                 197     998                   66.4%
  R                            68                                                            140                                 208                           
  Linezolid                    S                                                             851                                 43      894                   92.0%
  R                            29                                                            2                                   31                            
  Meropenem                    S                                                             201                                 144     345                   42.9%
  R                            47                                                            77                                  124                           
  Oxacillin                    S                                                             133                                 217     350                   14.6%
  R                            45                                                            513                                 558                           
  Piperacillin-tazobactam      S                                                             436                                 226     662                   48.7%
  R                            83                                                            150                                 233                           
  Rifampicin                   S                                                             376                                 7       383                   57.8%
  R                            53                                                            215                                 268                           
  Teicoplanin                  S                                                             912                                 29      941                   92.2%
  R                            45                                                            3                                   48                            
  Tobramycin                   S                                                             851                                 435     1286                  44.9%
  R                            133                                                           477                                 610                           
  Vancomycin                   S                                                             987                                 6       993                   98.7%
  R                            7                                                             0                                   7                             

**S**, susceptible clinical category; **R**, resistant clinical category.
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###### 

Percentage adequacy of the empirical prescription of an antibiotic if based on LRM recommendations with reference to the actual susceptibility of isolated bacteria by year and by type of infection.

  Type of Infection   2007    2008    2009    2010    2011    2012    2013    2014    2015    2016    2007--2016
  ------------------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------------
  **Respiratory**     58.4%   73.1%   62.2%   63.8%   55.5%   65.7%   60.1%   47.3%   50.0%   50.9%   57.6%
  **Bacteremia**      41.1%   41.7%   39.5%   41.8%   39.7%   37.5%   40.1%   46.0%   49.7%   38.1%   41.4%
  **Urinary**         78.5%   78.0%   59.4%   65.2%   48.9%   46.9%   43.1%   57.0%   51.0%   47.9%   54.9%
  **All**             54.8%   61.1%   53.1%   55.0%   48.1%   52.3%   50.5%   47.5%   50.1%   47.9%   51.9%
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###### 

Percentage adequacy of empirical antibiotic treatment by year and by type of infection.

  ----------------------- ---------- ---------- ---------------- ---------- ------------------------- ---------------- --------- --------- ---------------- --------- --------- ---------------- --------- --------- ---------------- --------- --------- -----
  **Type of Infection**   **2007**   **2008**   **2009**         **2010**   **2011**                  **2012**                                                                                                                                            
  **% adequacy**          ***N***    ***M***    **% adequacy**   ***N***    ***M***                   **% adequacy**   ***N***   ***M***   **% adequacy**   ***N***   ***M***   **% adequacy**   ***N***   ***M***   **% adequacy**   ***N***   ***M***   
  **Respiratory**         47.7%      132        53               65.9%      82                        46               52.5%     118       51               60.2%     161       83               49.3%     134       59               58.1%     105       57
  **Bacteremia**          46.9%      49         18               40.0%      120                       47               38.0%     92        42               34.9%     126       58               32.0%     125       51               50.5%     103       54
  **Urinary**             42.9%      7          5                44.4%      9                         6                16.7%     6         2                61.5%     13        7                22.2%     9         4                53.8%     13        9
  **All**                 47.3%      188        76               50.2%      211                       99               45.4%     216       95               49.7%     300       148              40.3%     268       114              54.3%     221       120
  **Type of Infection**   **2013**   **2014**   **2015**         **2016**   **Adequacy 2007--2016**                                                                                                                                                       
  **% adequacy**          ***N***    ***M***    **% adequacy**   ***N***    ***M***                   **% adequacy**   ***N***   ***M***   **% adequacy**   ***N***   ***M***   **% adequacy**   ***N***   ***M***                                        
  **Respiratory**         62.4%      93         60               48.8%      125                       61               63.6%     132       89               49.5%     107       61               55.4%     1189      620                                  
  **Bacteremia**          32.3%      96         46               37.9%      58                        29               40.0%     75        42               35.4%     48        24               38.3%     892       411                                  
  **Urinary**             62.5%      16         10               71.4%      7                         4                43.3%     30        18               66.7%     9         7                49.6%     119       72                                   
  **All**                 48.3%      205        116              46.3%      190                       103              53.6%     237       149              46.3%     164       92               48.2%     2200      1112                                 
  ----------------------- ---------- ---------- ---------------- ---------- ------------------------- ---------------- --------- --------- ---------------- --------- --------- ---------------- --------- --------- ---------------- --------- --------- -----

***N***, for each year, the total number of comparisons between empirically prescribed antibiotics and the result of in vitro susceptibility tests for each bacterium isolated in ICU patients; ***M***, for each year, the total number of bacteria isolated whose in vitro susceptibility study was compared to the empirical antibiotic treatment to calculate the percentage adequacy.
